# Emotional Well-being: Mechanistic Insights and Clinical Implications of the Gut-Brain Axis

Nino Rachvelishvili, Grigol Robakidze University, Georgia
Aisel Ajalieva-Akhverdova, Grigol Robakidze University, Georgia

The Asian Conference on Psychology & the Behavioral Sciences 2026
Official Conference Proceedings

## Abstract

Historically, researchers have treated gastrointestinal (GI) health and psychological Well-being as separate fields. Currently, however, the Microbiota-Gut-Brain Axis (MGBA) occupies the forefront of biomedical research. This bidirectional communication network links the central nervous system (CNS), the enteric nervous system (ENS), the hypothalamic-pituitary-adrenal (HPA) axis, and our immune defenses. Recent literature (2024–2025) demonstrates that GI dysfunction and microbial imbalances (dysbiosis) directly drive the underlying biology of stress, anxiety, and Major Depressive Disorder (MDD). Functionally, the gut microbiome operates as a supplementary endocrine organ. It facilitates the synthesis of crucial neurotransmitters like serotonin, GABA, and dopamine, while also managing immune responses through cytokines and producing neuroactive short-chain fatty acids (SCFAs). This review synthesizes contemporary evidence on how the MGBA operates across neurochemical, immune, and psychosocial levels. Furthermore, it critically evaluates practical clinical interventions, including psychobiotics, dietary modulation, Fecal Microbiota Transplantation (FMT), and Cognitive Behavioral Therapy (CBT). Elucidating these precise mechanisms establishes a robust foundation for treating mental health through personalized, integrative medicine.

*Keywords:* microbiota-gut-brain axis (MGBA), psychobiotics, neuroinflammation, intestinal permeability, stress resilience

iafor
The International Academic Forum
www.iafor.org

## Introduction: The Paradigm Shift to the "Holobiont"

Contemporary science increasingly conceptualizes the human body as a "holobiont"—a host existing in symbiotic partnership with trillions of microorganisms. From this perspective, the gastrointestinal tract emerges as a primary regulator of mental health. Historically, the gut was colloquially termed the "second brain" due to its extensive and autonomous Enteric Nervous System (ENS) (Mayer et al., 2015). Current paradigms recognize a continuous, dynamic bidirectional communication between the gut and the brain.

It is not coincidental that patients presenting with Irritable Bowel Syndrome (IBS) or functional dyspepsia frequently exhibit comorbid anxiety and depression. This overlap indicates a shared biological etiology within the MGBA (Zhu et al., 2025). The axis integrates neural signaling (predominantly via the vagus nerve), endocrine fluctuations (e.g., cortisol), and immune mediators (cytokines). As Binda et al. (2024) assert, delineating this bidirectional network is essential for a comprehensive understanding of emotional resilience and cognitive function. This review elucidates the specific mechanisms through which gastrointestinal health influences mood and highlights clinical therapies designed to concurrently treat psychiatric and digestive pathologies.

## The Architecture of the Axis: Neural and Endocrine Pathways

Gut-brain communication is predicated upon a highly specialized anatomical and functional infrastructure.

### The Vagus Nerve: The Neural Superhighway

The vagus nerve (Cranial Nerve X) constitutes the primary anatomical conduit of the MGBA. Although traditionally conceptualized as a top-down regulatory pathway, its anatomical composition reveals a predominantly afferent function. Approximately 80% to 90% of vagal nerve fibers are afferent, transmitting signals from the viscera to the brain (Binda et al., 2024). Consequently, the gut microbiome continuously relays environmental data to the brainstem's nucleus tractus solitarii (NTS). Subsequently, these signals propagate to the limbic system, the primary center for emotional regulation (Cryan et al., 2019).

### The Enteric Nervous System (ENS)

Despite being frequently overlooked, the ENS comprises over 100 million neurons—exceeding the neuronal count of the spinal cord. It utilizes upwards of 30 neurotransmitters identical to those in the central nervous system. Although capable of autonomous function, the ENS remains subject to modulation by the central nervous system via autonomic pathways. Dysregulation of ENS signaling typically manifests as functional gastrointestinal disorders. Notably, emerging research links these identical signaling deficits to the sensory processing abnormalities frequently observed in anxiety disorders (Gershon & Tack, 2007).

## Neurochemical Mechanisms: The Microbiota as a Chemical Factory

Neurotransmitters function as the brain's chemical messengers, governing stress responses, motivation, and mood regulation. A pivotal finding by Mehta et al. (2025) demonstrates a profound reliance on gut microbiota for the biosynthesis and regulation of these neurochemicals.

### Serotonin (5-HT) Biosynthesis

Enterochromaffin (EC) cells within the gastrointestinal epithelium synthesize approximately 90% of the body's serotonin (Gershon & Tack, 2007; Mehta et al., 2025). This peripheral serotonin is incapable of crossing the blood-brain barrier. Nevertheless, gut microbes modulate central serotonin levels by regulating the availability of its precursor, the amino acid tryptophan. Under inflammatory conditions, tryptophan metabolism is shunted toward the kynurenine pathway rather than serotonin synthesis. This metabolic shift generates neurotoxic metabolites, such as quinolinic acid, which are strongly implicated in the pathogenesis of depression (Zhu et al., 2025).

### Z and Dopamine

Intestinal microbiota also exerts a significant influence over dopamine and Gamma-Aminobutyric Acid (GABA) pathways.

- GABA: Specific strains of *Lactobacillus* and *Bifidobacterium* directly synthesize GABA. As the primary inhibitory neurotransmitter in the central nervous system, adequate GABA levels are essential for attenuating neuronal excitability and mitigating anxiety (Strandwitz, 2018).
- Dopamine: Integral to motivation and reward circuitry, dopamine is synthesized by several *Bacillus* strains. Dysbiosis within the gut microbiome can precipitate a decline in dopaminergic signaling. This reduction frequently manifests as anhedonia—the inability to experience pleasure—a hallmark symptom of numerous depressive disorders ("Probiotics, prebiotics, and psychobiotics" 2025; Smith & Berridge, 2024).

### Short-Chain Fatty Acids (SCFAs)

Microbial fermentation of dietary fiber yields Short-Chain Fatty Acids (SCFAs), predominantly acetate, propionate, and butyrate. Liu et al. (2023) and Zhu et al. (2025) emphasize the potent neuroactive properties of these SCFAs. They are capable of traversing the blood-brain barrier to execute several critical physiological functions:

- Microglial Maturation: They regulate the development and function of the brain's resident macrophages.
- Neurotrophic Factors: They upregulate Brain-Derived Neurotrophic Factor (BDNF), a protein essential for neuroplasticity and cognitive function.
- Epigenetic Regulation: They function as histone deacetylase (HDAC) inhibitors, modulating the expression of genes associated with stress resilience.

## The Inflammatory Hypothesis: Stress, "Leaky Gut," and Depression

Immunological pathways provide one of the most robust mechanistic explanations for the gut-mood connection. Zhu et al. (2025) detail the precise mechanisms by which microbial dysbiosis precipitates systemic inflammation.

### HPA Axis Dysregulation and Intestinal Permeability

Psychological stress and functional gastrointestinal disorders are highly comorbid. Chronic psychological stress induces sustained HPA axis activation, resulting in elevated cortisol levels. While acute cortisol spikes exert anti-inflammatory effects, chronic elevation compromises the integrity of the tight junctions lining the intestinal epithelium. This

degradation increases intestinal permeability, a pathological state clinically referred to as "leaky gut" syndrome (Foster et al., 2017).

### Metabolic Endotoxemia and Neuroinflammation

A compromised intestinal barrier permits the translocation of bacterial endotoxins, particularly Lipopolysaccharides (LPS), into systemic circulation. The immune system detects this circulating LPS, triggering the release of pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6) (Zhu et al., 2025).

These cytokines can either penetrate the blood-brain barrier or utilize vagal afferents to activate central microglial cells. Upon activation, microglia secrete neurotoxic compounds that impair neuronal function and suppress BDNF expression. This cascade induces "sickness behavior"—a state characterized by lethargy, social withdrawal, and depressive symptoms. Given the phenotypic overlap with Major Depressive Disorder (MDD), it is highly probable that in a subset of patients, depression is fundamentally an inflammatory pathology originating in the gastrointestinal tract (An et al., 2024).

## Stress Resilience and Psychosocial Implications

The gut-brain axis extends beyond fundamental neurochemistry, exerting a tangible impact on psychosocial functioning and stress adaptation.

### The Biology of Resilience

Recent findings by An et al. (2024) in *Nature Mental Health* demonstrate that an individual's capacity for stress resilience is intrinsically linked to their specific gut microbiome profile. Highly resilient individuals typically exhibit a highly diverse microbiome enriched with anti-inflammatory taxa. Conversely, individuals with high stress vulnerability generally display reduced microbial diversity and diminished SCFA production.

### Quality of Life

Enduring chronic gastrointestinal symptoms, such as bloating, abdominal pain, or erratic bowel habits, significantly diminishes an individual's quality of life. This burden frequently precipitates diminished self-esteem and social isolation (Gralnek et al., 2000). However, this relationship is bidirectional. Individuals with a healthy, balanced gut microbiome tend to exhibit greater emotional flexibility and improved coping mechanisms in the face of psychosocial stress (Binda et al., 2024). This underscores the necessity of addressing gastrointestinal health as a foundational component of building mental resilience.

## Clinical Implications and Integrative Interventions

This accumulating biological data is catalyzing a paradigm shift in clinical practice. The medical community is progressively adopting integrative therapeutic models, notably incorporating "psychobiotics."

### Psychobiotics: Precision Probiotics

"Psychobiotics" are defined as live microorganisms that confer mental health benefits when administered in adequate amounts (Binda et al., 2024). Current research substantiates the efficacy of several specific strains:

- *Lactobacillus rhamnosus*: This strain has been shown to attenuate cortisol levels and reduce anxiety via GABAergic pathway modulation.
- *Bifidobacterium longum*: Clinical studies indicate its capacity to enhance cognitive focus and alleviate generalized anxiety in healthy populations ("Probiotics, prebiotics, and psychobiotics" 2025).
- *Clostridium butyricum*: Preliminary data suggest it may augment the efficacy of standard antidepressant pharmacotherapy (Zhu et al., 2025).

### Dietary Modulation

Dietary modulation remains the most potent intervention for altering the microbiome.

- **Prebiotics:** These indigestible fibers, such as inulin and galactooligosaccharides, serve as substrates for beneficial bacteria, thereby promoting SCFA production.
- **Polyphenols:** Abundant in dark chocolate, tea, and berries, these compounds exert prebiotic-like effects and mitigate neuroinflammation (Xiong et al., 2023).
- **Fermented Foods:** Regular consumption of foods like kimchi, kefir, or yogurt introduces transient beneficial microbes that support immune homeostasis (Mehta et al., 2025).

### Fecal Microbiota Transplantation (FMT)

In cases where depression is predominantly driven by severe gut dysbiosis, Fecal Microbiota Transplantation (FMT) emerges as a potential therapeutic option. Zhu et al. (2025) note that transferring microbiota from a healthy donor to a depressed recipient significantly ameliorates depressive symptoms in murine models. Initial human trials yield promising results, although the standardization of clinical protocols remains a significant challenge.

### Cognitive Behavioral Therapy (CBT)

Psychotherapy exerts quantifiable biological effects. Cognitive Behavioral Therapy (CBT) functions as a top-down intervention. By mitigating perceived stress, CBT attenuates HPA axis hyperactivity. The subsequent reduction in cortisol facilitates the repair of the intestinal epithelium, allowing the microbiome to stabilize. The integration of CBT with psychobiotic therapy is rapidly emerging as the gold standard for holistic patient care (Loh et al., 2024).

## Limitations, Technology, and Future Directions

While research is advancing rapidly, significant methodological and clinical hurdles remain.

### Interindividual Variability

Garg (2025) emphasizes the profound interindividual variability of the microbiome. It is shaped by geography, diet, host genetics, and early-life environmental exposures. Consequently, a probiotic intervention that alleviates anxiety in one individual may prove inefficacious in another. To address this, the field must pivot toward personalized medicine, potentially

leveraging machine learning algorithms to predict individual microbial responses to targeted therapies (Xu, 2025).

### Emerging Technologies: Gut-on-a-Chip

The translational gap between murine models and human biology remains a significant limitation, as highlighted by Binda et al. (2024). To circumvent this, researchers are increasingly utilizing “gut-on-a-chip” technology. These microfluidic devices accurately simulate the physiological and mechanical environment of the human intestinal tract. They enable high-fidelity observation of gut-brain interactions, thereby accelerating the discovery and validation of novel psychobiotics and pharmacological agents.

## Conclusion

The Microbiota-Gut-Brain Axis has fundamentally revolutionized the conceptualization of mental health. It challenges the traditional neurocentric paradigm of psychiatry. Instead, it demonstrates that emotional Well-being is inextricably linked to the microbial ecology of the gastrointestinal tract.

The synthesized research unequivocally identifies immune dysregulation, neurotransmitter deficits, and gut dysbiosis as primary drivers of depression and anxiety. Conversely, maintaining a diverse and robust microbiome is essential for emotional and cognitive stability. Integrative treatments combining dietary modulation, psychobiotics, FMT, and traditional psychotherapy offer a tangible, biologically grounded approach to patient care. Ultimately, targeting gastrointestinal health may represent one of the most efficacious strategies for treating psychiatric disorders.

## Declaration of Generative AI and AI-Assisted Technologies in the Writing Process

During the preparation of this work, the author(s) used AI-assisted technologies (such as Large Language Models) solely to improve the language, clarity, and readability of the manuscript and to ensure the correct formatting of the reference list according to APA 7th Edition standards. After using these tools, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

## References

An, E., Delgadillo, D. R., Yang, J., Irimia, A., & Gupta, A. (2024). Stress-resilience impacts psychological Well-being as evidenced by brain–gut microbiome interactions. *Nature Mental Health*, *2*(8), 935–950. https://doi.org/10.1038/s44220-024-00266-6

Binda, S., Tremblay, A., Iqbal, U. H., Lemelin, M.-A., & Ismail, N. (2024). Psychobiotics and the microbiota–gut–brain axis: Where do we go from here? *Microorganisms*, *12*(4), 634. https://doi.org/10.3390/microorganisms12040634

Clapp, M., Aurora, N., Herrera, L., Bhatia, M., Wilen, E., & Wakefield, S. (2017). Gut microbiota's effect on mental health: The gut–brain axis. *Clinical Practice*, *7*(4), 987–995.

Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., Guzzetta, K. E., Jaggar, M., Long-Smith, C. M., Lyte, J. M., Martin, J. A., Moloney, G. M., Morelli, E., Morillas, E., O'Connor, R., ... Dinan, T. G. (2019). The microbiota–gut–brain axis. *Physiological Reviews*, *99*(4), 1877–2013.

Foster, J. A., Rinaman, L., & Cryan, J. F. (2017). Stress & the gut-brain axis: Regulation by the microbiome. *Neurobiology of Stress*, *7*, 124–136. https://doi.org/10.1016/j.ynstr.2017.03.001

Garg, G. (2025). Unlocking the therapeutic potential of gut microbiota for cognition and brain ageing. *Brain Research Bulletin*, *184*, 37–48.

Gershon, M. D., & Tack, J. (2007). The serotonin signaling system: From basic understanding to drug development for functional GI disorders. *Gastroenterology*, *132*(1), 397–414.https://doi.org/10.1053/j.gastro.2006.11.002

Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., & Mayer, E. A. (2000). The impact of irritable bowel syndrome on health-related quality of life. *Gastroenterology*, *119*(3), 654–660.

Liu, L., Wang, H., Chen, X., Zhang, Y., Zhang, H., & Zhao, J. (2023). Gut microbiota and its metabolites in depression: From pathogenesis to treatment. *EBioMedicine*, *90*, 104527.

Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, S. X., Chan, H. H., Yeow, S. H., Foo, J. B., Koh, R. Y., & Lim, W. M. (2024). Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. *Signal Transduction and Targeted Therapy*, *9*(1), 37.

Mayer, E. A., Labus, J. S., Tillisch, K., Cole, S. W., & Baldi, P. (2015). Towards a systems view of IBS. *Nature Reviews Gastroenterology & Hepatology*, *12*(10), 592–605.

Mehta, I., Juneja, K., Nimmakayala, T., & Agrawal, A. (2025). Gut microbiota and mental health: A comprehensive review of gut–brain interactions in mood disorders. *Cureus*, *17*(1), e75421. https://doi.org/10.7759/cureus.75421

Probiotics, prebiotics, and psychobiotics: Clinical perspectives in mental health. (2025). *International Journal of Microbiome Studies, 10*(2)*,* 960–978.

Smith, K. S., & Berridge, K. C. (2024). The brain's reward circuitry: Understanding anhedonia and motivational deficits through the microbiota-gut-brain axis. *Neuroscience & Biobehavioral Reviews, 158,* 105542. https://doi.org/10.1016/j.neubiorev.2024.105542

Strandwitz, P. (2018). Neurotransmitter modulation by the gut microbiota. *Brain Research*, *1693*(Pt B), 128–133. https://doi.org/10.1016/j.brainres.2018.03.015

Xiong, R.-G., Li, J., Cheng, J., Zhou, S.-S., Wu, S.-X., Huang, S.-Y., Saimaiti, A., Yang, Z.-J., & Li, H.-B. (2023). The role of gut microbiota in anxiety, depression, and other mental disorders as well as the protective effects of dietary components. *Trends in Food Science & Technology*, *138*, 44–56.

Xu, J. (2025). The microbiota–gut–brain axis and its role in neurological disorders. *Frontiers in Microbiology*, *16*, 1583562.

Yuan, Y., Cheng, Y., Pan, W., & Liu, X. (2025). Gut microbiota variations in depression and anxiety: A systematic review. *Microbial Ecology in Health and Disease*, *37*(1).

Zhu, Z., Cheng, Y., Liu, X., Yuan, Y., & Pan, W. (2025). The microbiota-gut-brain axis in depression: Unraveling the relationships and therapeutic opportunities. *Frontiers in Immunology*, *16*, 1644160. https://doi.org/10.3389/fimmu.2025.1644160